Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Debt to Equity (2016 - 2025)

Immucell (ICCC) has disclosed Debt to Equity for 16 consecutive years, with $0.32 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Debt to Equity fell 22.85% year-over-year to $0.32, compared with a TTM value of $0.32 through Sep 2025, down 22.85%, and an annual FY2024 reading of $0.38, down 20.03% over the prior year.
  • Debt to Equity was $0.32 for Q3 2025 at Immucell, down from $0.33 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.48 in Q4 2023 and bottomed at $0.28 in Q4 2021.
  • Average Debt to Equity over 5 years is $0.36, with a median of $0.34 recorded in 2022.
  • The sharpest move saw Debt to Equity skyrocketed 44.53% in 2023, then decreased 22.85% in 2025.
  • Year by year, Debt to Equity stood at $0.28 in 2021, then rose by 20.03% to $0.34 in 2022, then skyrocketed by 42.21% to $0.48 in 2023, then decreased by 20.03% to $0.38 in 2024, then dropped by 16.84% to $0.32 in 2025.
  • Business Quant data shows Debt to Equity for ICCC at $0.32 in Q3 2025, $0.33 in Q2 2025, and $0.35 in Q1 2025.